Literature DB >> 16396920

Intraabdominal tissue concentration of ertapenem.

M Wittau1, E Wagner, V Kaever, T Koal, D Henne-Bruns, R Isenmann.   

Abstract

OBJECTIVES: Ertapenem, a class I carbapenem, is approved for the treatment of mild to severe intraabdominal infections, but its in vivo concentrations in intraabdominal tissues are unknown. The purpose of this study was to determine the concentration of ertapenem in intraabdominal tissue. PATIENTS AND METHODS: After informed consent 48 patients, 23 female and 25 male with a median age of 58 years (34-81), requiring surgical intervention at intraabdominal organs were enrolled. Patients received 1 g of ertapenem intravenously for perioperative prophylaxis. Tissue samples were taken after resection of parts of the organs. Plasma samples were taken when tissue samples were taken. Drug concentrations were determined by liquid chromatography/mass spectrometry. An ANCOVA test (analysis of covariance) was performed to assess organ-specific differences in ertapenem concentration and penetration ratios.
RESULTS: Mean+/-SD ertapenem tissue concentration (mg/kg) was 16.0+/-8.8 in the gall bladder, 12.1+/-5.3 in the colon, 7.0+/-5.7 in the small bowel, 4.5+/-2.3 in the liver and 3.4+/-2.9 in the pancreas. The mean tissue/plasma ratio was 0.19 (colon), 0.17 (small bowel), 0.17 (gall bladder), 0.088 (liver) and 0.095 (pancreas). The ANCOVA test revealed statistically significant organ-specific differences in ertapenem tissue concentration in the gall bladder versus liver/pancreas and in tissue penetration for the colon versus liver/pancreas.
CONCLUSIONS: These pharmacokinetic results support the assumption that ertapenem is suitable for the treatment of intraabdominal infections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16396920     DOI: 10.1093/jac/dki459

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery.

Authors:  Mathias Wittau; Stephan Paschke; Max Kurlbaum; Jan Scheele; Neang S Ly; Evelyn Hemper; Marko Kornmann; Doris Henne-Bruns; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

2.  Activity of moxifloxacin, imipenem, and ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in monocultures and mixed cultures in an in vitro pharmacokinetic/pharmacodynamic model simulating concentrations in the human pancreas.

Authors:  Sabine Schubert; Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

Review 3.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  2019 WSES guidelines for the management of severe acute pancreatitis.

Authors:  Ari Leppäniemi; Matti Tolonen; Antonio Tarasconi; Helmut Segovia-Lohse; Emiliano Gamberini; Andrew W Kirkpatrick; Chad G Ball; Neil Parry; Massimo Sartelli; Daan Wolbrink; Harry van Goor; Gianluca Baiocchi; Luca Ansaloni; Walter Biffl; Federico Coccolini; Salomone Di Saverio; Yoram Kluger; Ernest Moore; Fausto Catena
Journal:  World J Emerg Surg       Date:  2019-06-13       Impact factor: 5.469

5.  Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem.

Authors:  Fausto de Lalla
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

Review 6.  Clinical practice guideline: management of acute pancreatitis.

Authors:  Joshua A Greenberg; Jonathan Hsu; Mohammad Bawazeer; John Marshall; Jan O Friedrich; Avery Nathens; Natalie Coburn; Gary R May; Emily Pearsall; Robin S McLeod
Journal:  Can J Surg       Date:  2016-04       Impact factor: 2.089

7.  Single Dose Based Ertapenem Prophylaxis Reduces Surgical Site Infection after Selective Hepatectomy of Hepatocellular Carcinoma: A Propensity Score Matching Study.

Authors:  Bin Tang; Xiaolin Liu; Fei Xing; Chao Wang; Changjun Jia; Songlin Peng; Yang Zhao; Chaoliu Dai; Feng Xu
Journal:  Biomed Res Int       Date:  2018-08-30       Impact factor: 3.411

8.  Impact of prior antibiotics on infected pancreatic necrosis microbiology in ICU patients: a retrospective cohort study.

Authors:  Charlotte Garret; Emmanuel Canet; Stéphane Corvec; David Boutoille; Matthieu Péron; Isabelle Archambeaud; Aurélie Le Thuaut; Jean-Baptiste Lascarrou; Frédéric Douane; Marc Lerhun; Nicolas Regenet; Emmanuel Coron; Jean Reignier
Journal:  Ann Intensive Care       Date:  2020-06-15       Impact factor: 6.925

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.